Dynavax TechnologiesDVAX
DVAX
About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Employees: 405
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
240% more call options, than puts
Call options by funds: $2.61M | Put options by funds: $768K
8% less funds holding
Funds holding: 280 [Q1] → 259 (-21) [Q2]
7.79% less ownership
Funds ownership: 102.86% [Q1] → 95.07% (-7.79%) [Q2]
25% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 55
32% less capital invested
Capital invested by funds: $1.66B [Q1] → $1.13B (-$523M) [Q2]
46% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 118
50% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$32
208%
upside
Avg. target
$32
208%
upside
High target
$32
208%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Roy Buchanan | 208%upside $32 | Market Outperform Reiterated | 22 Aug 2025 |
Financial journalist opinion
Based on 8 articles about DVAX published over the past 30 days
Positive
Reuters
5 days ago
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-stage study.
Neutral
PRNewsWire
5 days ago
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral vaccine response rate at the dose selected for advancement, with comparable immunogenicity to Shingrix Dynavax selects the optimal dose of Z-1018 for advancement to Part 2 of Phase 1/2 trial in adults 70 years of age and older, expected to initiate in 2H 2025 EMERYVILLE, Calif. , Aug. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced positive topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years.
Positive
Seeking Alpha
2 weeks ago
Dynavax Technologies: A Dip To Accumulate
Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and management is projecting significant sales and market share growth through 2030. Dynavax boasts a robust balance sheet, recently completed a $200M buyback, and is well-regarded by analysts, supporting further accumulation at current valuations.
Neutral
Seeking Alpha
2 weeks ago
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Senior VP & CFO Paul Cox - VP of Investor Relations & Corporate Communications Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Ryan Spencer - CEO & Director Conference Call Participants Douglas Royal Buchanan - Citizens JMP Securities, LLC, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Matthew Christopher Phipps - William Blair & Company L.L.C., Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Philip M.
Positive
Zacks Investment Research
2 weeks ago
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago.
Positive
The Motley Fool
2 weeks ago
Dynavax (DVAX) Q2 Revenue Jumps 29%
Dynavax (DVAX) Q2 Revenue Jumps 29%
Neutral
PRNewsWire
2 weeks ago
Dynavax Reports Second Quarter 2025 Financial Results
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 million Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025 Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant program Conference call today at 4:30 p.m. ET/1:30 p.m.
Neutral
PRNewsWire
3 weeks ago
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close.
Positive
Reuters
2 months ago
Dynavax elects all four of its nominees after Deep Track proxy fight
Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.
Neutral
PRNewsWire
2 months ago
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors.
Charts implemented using Lightweight Charts™